← Russell 3000 cross-section

HROW HARROW, INC.

Trailing twelve months to 2026-06-30 · as filed 2026-08-10, not restated
Healthcare

Scale

Market cap
$1.4bn
Revenue TTM
$276m
Net income TTM
$-37m
Free cash flow
$5m
Composite score
Sector rank
#1816

Valuation

P / E
EV / EBITDA
EV / sales
4.9
FCF yield
0.35%
Earnings yield vs 10-yr
-7.31pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-13.5%
EBITDA margin
ROE
-244.9%
ROIC
Revenue growth
21.1%

Insider activity, last 90 days

Net open-market
$-0.45m
Buyers
0
Sellers
1

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

As consideration for the Acquisition, we will pay Viatris $30,000,000 in cash at the closing of the Acquisition (the “Closing”) and have agreed to pay up to an additional $70,000,000 in contingent milestone payments, payable if specified annual net sales thresholds for TYRVAYA are achieved in certain calendar years following the Closing. The decrease in compounding revenue was primarily due to a decrease in volume and the discontinuation of sales of our Klarity-C compounded formulation which occurred during the second quarter of 2025. …HARROW, INC., 10-Q, period ended 2026-06-30, filed 2026-08-10

Read the full passage →